Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. NAVN
10. DFTX

Go back to Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 17.65 --0 (-0%)
Previous Close $17.65    52 Week High $63.73 
Open $17.65    52 Week Low $8.00 
Day High $17.65    P/E N/A 
Day Low $17.65    EPS $-5.69 
Volume 431